Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-7080a in nAMD and DME
NCT02530918Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DS-7080a in neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME) (6 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Treatment-Emergent Adverse Events at 16 weeks and Best Corrected Visual Acuity at 12 weeks. Started Jul 2015; status: completed.
02
Drugs
DS-7080a
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02530918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530918.